316 related articles for article (PubMed ID: 30279220)
1. Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses.
Ben Bdira F; Artola M; Overkleeft HS; Ubbink M; Aerts JMFG
J Lipid Res; 2018 Dec; 59(12):2262-2276. PubMed ID: 30279220
[TBL] [Abstract][Full Text] [Related]
2. New insights into lactase and glycosylceramidase activities of rat lactase-phlorizin hydrolase.
Büller HA; Van Wassenaer AG; Raghavan S; Montgomery RK; Sybicki MA; Grand RJ
Am J Physiol; 1989 Oct; 257(4 Pt 1):G616-23. PubMed ID: 2508486
[TBL] [Abstract][Full Text] [Related]
3. Activity-Based Probes for Glycosidases: Profiling and Other Applications.
Kuo CL; van Meel E; Kytidou K; Kallemeijn WW; Witte M; Overkleeft HS; Artola ME; Aerts JM
Methods Enzymol; 2018; 598():217-235. PubMed ID: 29306436
[TBL] [Abstract][Full Text] [Related]
4. Location of the two catalytic sites in intestinal lactase-phlorizin hydrolase. Comparison with sucrase-isomaltase and with other glycosidases, the membrane anchor of lactase-phlorizin hydrolase.
Wacker H; Keller P; Falchetto R; Legler G; Semenza G
J Biol Chem; 1992 Sep; 267(26):18744-52. PubMed ID: 1388157
[TBL] [Abstract][Full Text] [Related]
5. In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.
Kuo CL; Kallemeijn WW; Lelieveld LT; Mirzaian M; Zoutendijk I; Vardi A; Futerman AH; Meijer AH; Spaink HP; Overkleeft HS; Aerts JMFG; Artola M
FEBS J; 2019 Feb; 286(3):584-600. PubMed ID: 30600575
[TBL] [Abstract][Full Text] [Related]
6. Glucosylceramidases and malignancies in mammals.
Astudillo L; Therville N; Colacios C; Ségui B; Andrieu-Abadie N; Levade T
Biochimie; 2016 Jun; 125():267-80. PubMed ID: 26582417
[TBL] [Abstract][Full Text] [Related]
7. Sequence, structural, functional, and phylogenetic analyses of three glycosidase families.
Mian IS
Blood Cells Mol Dis; 1998 Jun; 24(2):83-100. PubMed ID: 9779294
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-based inhibitors of glycosidases: design and applications.
Kallemeijn WW; Witte MD; Wennekes T; Aerts JM
Adv Carbohydr Chem Biochem; 2014; 71():297-338. PubMed ID: 25480507
[TBL] [Abstract][Full Text] [Related]
9. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease.
Dvir H; Harel M; McCarthy AA; Toker L; Silman I; Futerman AH; Sussman JL
EMBO Rep; 2003 Jul; 4(7):704-9. PubMed ID: 12792654
[TBL] [Abstract][Full Text] [Related]
10. Specificity of human glucosylceramide beta-glucosidase towards synthetic glucosylsphingolipids inserted into liposomes. Kinetic studies in a detergent-free assay system.
Sarmientos F; Schwarzmann G; Sandhoff K
Eur J Biochem; 1986 Nov; 160(3):527-35. PubMed ID: 3780720
[TBL] [Abstract][Full Text] [Related]
11. [The active site of human glucocerebrosidase: structural predictions and experimental validations].
Fabrega S; Durand P; Mornon JP; Lehn P
J Soc Biol; 2002; 196(2):151-60. PubMed ID: 12360744
[TBL] [Abstract][Full Text] [Related]
12. Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish.
Lelieveld LT; Mirzaian M; Kuo CL; Artola M; Ferraz MJ; Peter REA; Akiyama H; Greimel P; van den Berg RJBHN; Overkleeft HS; Boot RG; Meijer AH; Aerts JMFG
J Lipid Res; 2019 Nov; 60(11):1851-1867. PubMed ID: 31562193
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Wong YC; Krainc D
Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
[TBL] [Abstract][Full Text] [Related]
14. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
Atrian S; López-Viñas E; Gómez-Puertas P; Chabás A; Vilageliu L; Grinberg D
Proteins; 2008 Feb; 70(3):882-91. PubMed ID: 17803231
[TBL] [Abstract][Full Text] [Related]
15. Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy.
Kacher Y; Brumshtein B; Boldin-Adamsky S; Toker L; Shainskaya A; Silman I; Sussman JL; Futerman AH
Biol Chem; 2008 Nov; 389(11):1361-9. PubMed ID: 18783340
[TBL] [Abstract][Full Text] [Related]
16. Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy.
Yap TL; Jiang Z; Heinrich F; Gruschus JM; Pfefferkorn CM; Barros M; Curtis JE; Sidransky E; Lee JC
J Biol Chem; 2015 Jan; 290(2):744-54. PubMed ID: 25429104
[TBL] [Abstract][Full Text] [Related]
17. Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations.
Alfonso P; Pampín S; Estrada J; Rodríguez-Rey JC; Giraldo P; Sancho J; Pocoví M
Blood Cells Mol Dis; 2005; 35(2):268-76. PubMed ID: 16039881
[TBL] [Abstract][Full Text] [Related]
18. Normalization of liver glucosylceramide levels in the "Gaucher" mouse by phosphatidylserine injection.
Datta SC; Radin NS
Biochem Biophys Res Commun; 1988 Apr; 152(1):155-60. PubMed ID: 3358758
[TBL] [Abstract][Full Text] [Related]
19. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
[TBL] [Abstract][Full Text] [Related]
20. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
